| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcaa03b795cd8da869d58e8f28bf52e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_157f6ea8a2b996328769d9b5e934655f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-04 |
| filingDate |
2021-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30929c3fa36a570dcc1c72bb677f6cfb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_174f6685d2ee0a6a49e30878b1d19167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e82370963810974eaa9fa58c62e8067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b8658ddda877812e56d230c55815879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7372efbdf42ace163427fc145431888
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5efbbb8cea3693f63b1ba9beae4debb |
| publicationDate |
2022-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-115197203-A |
| titleOfInvention |
Aniline pyrimidine compound, its preparation method and application |
| abstract |
The invention discloses an aniline pyrimidine compound, a preparation method and application thereof. The present invention specifically discloses an anilidine compound represented by formula I or a pharmaceutically acceptable salt thereof, as well as a preparation method and application thereof in the preparation of a medicament for treating cancer. The aniline compound of the present invention can not only inhibit the double mutation of EGFR L858R/T790M, but also has a good inhibitory effect on the triple mutation of EGFR L858R/T790M/C797S. |
| priorityDate |
2021-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |